UPDATE: JP Morgan Downgrades Optimer Pharmaceuticals to Perform on Near-Term Outlook

JP Morgan reduced its rating on Optimer Pharmaceuticals

from Outperform to Perform. JP Morgan noted, "We are downgrading shares of OPTR on the deceleration of DIFICID script growth which may be partially attributable to the availability of generic Vancocin. Longer term, scripts may be adversely impacted post expiration of the CBST co- promote agreement in 4/2013." Optimer Pharmaceuticals closed at $11.46 on Monday.